Mettler Toledo

MTD Health Care Market cap $25.8B as of Sep 14, 2026 16:00 ET S&P 500

Q2 FY26 Apr 1 – Jun 30, 2026 reported Jul 31, 2026

Revenue$1.03B +4% year over year

Gross profit$0.65B 63% margin

Operating profit$0.33B 33% margin

Net profit$0.23B 23% margin

The numbers behind the diagram

All figures in billions of U.S. dollars, for Q2 FY26 (period ends Jun 30, 2026).
Item	Value	Share of revenue	Year over year
Revenue	1.03	100%	+4%
Laboratory	0.55	54%	+3%
Industrial	0.42	41%	+6%
Retail	0.06	5%	+13%
Cost of revenue	−0.38	37%
Gross profit	0.65	63% margin	+4pp
R&D	−0.05	5%	+0pp
SG&A	−0.26	26%
Operating profit	0.33	33% margin
Interest & other costs	−0.04
Tax	−0.06
Net profit	0.23	23% margin	+2pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Mar 31, 2026).
Item	Value	Share of revenue	Year over year
Revenue	0.95	100%	+7%
Laboratory related	0.53	55%	+5%
Industrial related	0.38	40%	+10%
Retail related	0.05	5%	+13%
Cost of revenue	−0.39	41%
Gross profit	0.56	59% margin	−1pp
R&D	−0.05	6%	+0pp
SG&A	−0.26	27%	+0pp
Operating profit	0.25	26% margin	+0pp
Interest & other costs	−0.04
Tax	−0.04
Net profit	0.17	18% margin	−1pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Sep 30, 2025).
Item	Value	Share of revenue	Year over year
Revenue	1.03	100%	+8%
Laboratory	0.57	55%	+6%
Industrial	0.41	39%	+11%
Retail	0.06	6%	+8%
Cost of revenue	−0.42	41%
Gross profit	0.61	59% margin	−1pp
R&D	−0.05	5%	+0pp
SG&A	−0.25	24%	+0pp
Operating profit	0.31	30% margin	+0pp
Interest & other costs	−0.04
Tax	−0.05
Net profit	0.22	21% margin	−1pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q2 FY25 (period ends Jun 30, 2025).
Item	Value	Share of revenue	Year over year
Revenue	0.98	100%	+4%
Laboratory	0.54	55%	+3%
Industrial	0.40	40%	+5%
Retail	0.05	5%	+3%
Cost of revenue	−0.40	41%
Gross profit	0.58	59% margin	−1pp
R&D	−0.05	5%	+0pp
SG&A	−0.20	20%	+0pp
Operating profit	0.33	34% margin	+0pp
Interest & other costs	−0.09
Tax	−0.05
Net profit	0.20	21% margin	−3pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

Financial health

The balance sheet, the quarter's capital flow, the debt schedule and the capital structure of the quarter shown above.

Every set of results we hold, newest first. Open one on its own page.

Quarter	Period	Reported	Revenue	Year over year	Operating margin	Net profit	Net margin
Q2 FY26 Apr 1 – Jun 30, 2026 reported Jul 31, 2026 Operating margin 33% Net profit $0.23B	Apr 1 – Jun 30, 2026	Jul 31, 2026	$1.03B	+4%	33%	$0.23B	23%
Q1 FY26 Jan 1 – Mar 31, 2026 reported May 8, 2026 Operating margin 26% Net profit $0.17B	Jan 1 – Mar 31, 2026	May 8, 2026	$0.95B	+7%	26%	$0.17B	18%
Q3 FY25 Jul 1 – Sep 30, 2025 reported Nov 7, 2025 Operating margin 30% Net profit $0.22B	Jul 1 – Sep 30, 2025	Nov 7, 2025	$1.03B	+8%	30%	$0.22B	21%
Q2 FY25 Apr 1 – Jun 30, 2025 reported Aug 1, 2025 Operating margin 34% Net profit $0.20B	Apr 1 – Jun 30, 2025	Aug 1, 2025	$0.98B	+4%	34%	$0.20B	21%